Monoclonal antibodies and compositions comprising such useful for inhibition of .alpha.v.beta.5 mediated angiogenesis
CA 2754102 C · Owner: The Scripps Research Institute · Inventors: Cheresh, David A.; Friedlander, Martin; Brooks, Peter
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention describes methods for inhibiting angiogenesis in tissues using vitronectin .alpha.v.beta.5 antagonists. The present invention provides monoclonal antibodies and compositions comprising such, which are useful in the inhibition of .alpha.v.beta.5 mediated angiogenesis. The .alpha.v.beta.5- mediated angiogenesis is correlated with exposure to cytokines including vascular endothelial growth factor transforming growth factor-.alpha. and epidermal growth factor. Inhibition of .alpha.v.beta.5-mediated angiogenesis is particularly preferred in vascular endothelial ocular neovascular diseases in tumor growth and in inflammatory conditions using therapeutic compositions …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 13, 1996 and granted December 18, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 13, 2016.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 13, 2018.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.